Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Xenon Pharmaceuticals Inc. (XENE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3 epilepsy programs including in X-TOLE2 and X-TOLE3 clinical trials in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures Xenon to host XEN1101 MDD Webinar in mid-September to discuss Kv modulation in MDD, the X-NOVA clinical trial and the broader MDD landscape Conference call at 4:30 pm ET today"
08/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover"
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/31/2023 144 Form 144 - Report of proposed sale of securities:
05/30/2023 144 Form 144 - Report of proposed sale of securities:
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical trials Anticipate last patient to be screened next month in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in fourth quarter Conference call at 4:30 pm ET today"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders: Date of meeting: June 1, 2023 Record date for notice: April 4, 2023 Record date for voting: April 4, 2023 Beneficial ownership determination date: April 4, 2023 Securities entitled to notice: Common Shares Securities entitled to vote: Common Shares Issuer mailing directly to non objecting beneficial owners: No Issuer will pay for objecting beneficial owner material distribution: Yes Issuer using notice-and-access for registered investors: No Issuer using notice-and-access for non-registered investors: No Notice-and-access stratification criteria: N/A Yours very truly, /s/ John Lundberg John ..."
03/01/2023 10-K Annual Report for the period ended December 31, 2022
03/01/2023 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder expected in third quarter Conference call at 4:30 pm ET today"
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
11/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
Docs: "Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year"
06/23/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/23/2022 8-K Quarterly results
06/22/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/21/2022 8-K Quarterly results
06/02/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/02/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/22/2022 8-K Unregistered Sales of Equity Securities  Interactive Data
03/10/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SEDAR filing submitted March 10, 2022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy